Privacy preferences
Inderes uses cookies to provide a better user experience and a personalised service. By consenting to the use of cookies, we can develop an even better service and will be able to provide content that is interesting to you.
  • Forum
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Morning ReviewDaily market recap and key overnight highlights
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • PortfolioInderes model portfolio
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Short SellingSee which listed companies have disclosed short interest
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Instagram
  • Facebook
  • X (Twitter)
Get in touch
  • info@inderes.se
  • +46 8 411 43 80
  • Vattugatan 17, 5tr
    111 52 Stockholm
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Q&A
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Transcripts

Read transcripts of webcasts and audiocasts

Transcripts

Read transcripts of webcasts and audiocasts

All regions
Sweden
Finland
Denmark
Norway
Latest
Trending
Followed

BioGaia, Audiocast with teleconference, Q1'24

By Inderes5/7/2024, 7:30 AM
BioGaia

Disclaimer: This is a machine-generated transcript and may contain inaccuracies.

Theresa Agnew
00:00 - 03:01

Hi, this is Theresa Agnew. We're here for our Q1 results. In Q1, our sales were 370 million SEK, which is an increase of 1%, primarily driven by growth in Asia Pacific and Europe, Middle East, Africa. This is despite record high sales in Q1 of 2023. So we were lapping the strongest quarter we've ever had at BioGaia. Sales in EMEA increased by 13% and in Asia Pacific by 6%, while the Americas region decreased by 14%. Our EBIT of 143 million SEK decreased by 3%, and our EBIT margin for Q1 is at 39%. We had a number of key events and launches in the quarter. In France, we launched Biogaia Prodentis for dentists. At BioGaia Canada, we launched a new skin health product called BioGaia Aldermis. We had previously launched Alkermes in the US in 2023, and due to the success of that launch, we decided to launch in Canada in March of 2024. The US business also launched a new product range called BioGaia Nurture & Grow, which focuses on gut health, immune health, and oral health. Our sales by segment for the pediatrics business decreased by 4%. This is primarily due to the Americas, mainly in the US, where last year we had sales of the Gerber product, where Gerber has discontinued the BioGaia products. So now we are lapping that discontinuation in 2023 as well as Brazil. We had a phasing of large orders in Q4 of 2023. So lower orders in Q1 in Brazil. Our adult sales increased by 32%, and this is mainly due to our sub-brand Gastrus in the US and Spain, as well as for dentists in the US and Germany. In terms of the regions. As I said before, Europe, Middle East, Africa increased by 13%. This was mainly in Spain, South Africa, the UAE. In Asia Pacific increased by 6%, primarily in Indonesia, Japan, and Thailand. And as I said previously, America has decreased by 14%, mainly Brazil, Mexico, and the US. And now Alex will take you through the specifics on the financials.

Alexander Kotsinas
03:03 - 07:43

Thank you, Theresa. So to summarize, like we heard, we had total revenues of 370 million, which is 1% growth compared to the same quarter in the previous year. And we have an operating profit of 143 million, which is a 3% decline compared to the same quarter in the last year. The margin was 39% and the earnings per share were at 1.21 cents per share. Operating cash flow was 52 million versus 98 million last year. If we look at the organic growth, we had an organic growth of 2% and a negative currency effect of 1%. So the currency effect in the quarter was quite small. Moving on to the gross margin, our overall margin was stable at 72%. Within Pediatrics, margin increased from 73% to 75%. And within adult health, it declined from 63% to 57%. The main reason for the variations in the margin, especially in adult health, is changes in the product mix. For example, as we mentioned previously, we had a quite large increase in sales in products like Gastrus. And, you know, those products have slightly lower gross margins than, for example, the protective tablets. So that explains why the mix change in the quarter explains why the margin is somewhat lower for the adult segment. Moving on to the operating expenses. Our operating expenses increased by 7%. If we look at the different lines, we see that our sales and marketing costs grew by 9%, mainly due to a higher activity level in different markets. As for the R&D costs, these costs grew by 34%. However, we have to remember they grew from a lower base. Due to that, we had quite low costs last year and the year before due to Covid restrictions on clinical studies. And we're more normalizing the costs now. That is why costs are increasing within R&D. Look at the administration. The costs grew from 4% to 2%. The cost here includes expenses for litigation. In Italy, and we have a total of extraordinary costs of about 5 million, which is mainly this line of admin costs. Then we have a line called other opex, which was a positive of 12 million versus 2 million last year. And this is due to an increase in exchange gains. So we have, so to speak, a negative cost here. So total opex then is 122 million. And then if you exclude adjustments of 5 million, we have an opex of 118 million versus 112 million. So it grew by 5%. If you would deduct the one-off items. Look at the P&L to summarize. Then sales grew by 1%, opex by 7%, and the EBIT decreased by 3%. We have a margin of 40%, 39%. And excluding the one-offs, a margin of 40% versus 41% last year. Looking at the cash flow. Cash flow from operating activities decreased by 47% to 52 million versus 98 million. And this is mainly due to higher costs in working capital resulting from increased receivables. We don't think there's anything special. It's more normal fluctuations within and between the quarters that cause this. So we will see in the coming quarter that the cash flow from those receivables will come in, and then the cash flow for the period is down 41 million and cash at the end of the period is 1.6 billion SEK. And as we announced before, we will pay out dividends, that will be decided by our annual general meeting today. There will be some dividend payments of 6.9, six per share, and a total of approximately 700 million out of that cash position, or 1.6 billion SEK. And with that, I hand over to Theresa for some concluding remarks.

Theresa Agnew
07:44 - 09:08

So in summary, despite record high sales in our same period, Q1 2023, our Q1 sales grew 1%. Our region of Europe, Middle East, Africa is back to growth with an increase of 13%. This is due to some of the markets we discussed such as the UK, Spain, and the United Arab Emirates. Asia Pacific continues on its solid growth trajectory, with 6% growth in markets such as Japan, Thailand, and Indonesia. And we also saw continuing growth in China, as we did in 2023, and Americas sales decreased by 14%, as discussed, mainly due to Brazil, Mexico, and the US. As we said, US sales were negatively affected by the discontinuation of the Gerber products, and Brazilian sales were negatively affected by the inventory buildup in Q4 of 2023 due to the launch of our protective drops. Easy Dropper, which is a novel innovation, and the Brazilian market is very excited about that launch for this year. Our operating expenses grew by 7%. As Alex detailed, our EBIT margin holds at 39%. So we will take any questions that you have.

Operator
09:12 - 09:35

If you wish to ask a question, please dial Pound Key five on your telephone keypad to enter the queue. If you wish to withdraw your question, please dial Pound Key six on your telephone keypad. The next question comes from Christopher Lederberg at Carnegie. Please go ahead.

Unknown 1
09:39 - 10:25

Hi. Good morning. I have three questions. I wonder if it's possible to quantify the negative effect from Gerber in the US. And for how long do you expect this negative year-over-year impact to continue? For example, did you have any sales to them back in the third and fourth quarter last year? And then I wonder if you could comment on the situation with distributors in Italy and whether you will continue to have legal costs in the coming quarters. And finally, I'm sorry, I just missed what you said about receivables. If you could give some explanation there on why they were tied up so much in the quarter. Thank you.

Unknown 2
10:25 - 10:26

Okay.

Theresa Agnew
10:26 - 11:19

So, the first question relates to the negative impact on Gerber. We do anticipate that this will continue this year because there were orders last year in Q2 as well as throughout the year. I would say the Q1 orders were larger than those in other quarters, but we will still be lapping those orders from 2023. In terms of Italy, our legal costs will continue because our arbitration is proceeding as scheduled. So, we anticipate these legal costs to continue; I'm not sure of the exact quarter, but it will be through most of the remainder of the year. And then I'll let Alex answer the question about receivables.

Unknown 2
11:19 - 11:20

Yes.

Alexander Kotsinas
11:20 - 11:36

So, the receivables. What I meant was that we have normal fluctuations in certain quarters. We have some orders coming in closer to the end of the quarter or at the beginning of the quarter. So, it's more of a normal variation. It's nothing strange with the receivables.

Unknown 1
11:38 - 11:48

Could I ask a follow-up? So, regarding Gerber, it's impossible to say how much negative impact that had on year-over-year growth in the quarter.

Alexander Kotsinas
11:51 - 12:04

No, we won't quantify it, but it had a substantial effect. Enough so that it was a large enough effect for us to mention it, so to speak. So, it did have an effect on the Americas' total.

Unknown 2
12:04 - 12:05

Okay. Yes.

Unknown 1
12:05 - 12:27

And, I think you have previously said that the target is to accelerate sales growth. So, my question is, even with this effect, for the full year, do you expect you could still achieve reported organic sales growth? Double-digit growth.

Theresa Agnew
12:28 - 13:05

So, we don't give guidance around the upcoming quarters. But as we look at our growth trajectory, there will be certain markets where we will be making some targeted investments. Some of those investments will be in marketing, in terms of sales force. So, these do take some time to then see the corresponding growth. So, we will be starting some of those investments in the future. But we don't particularly quantify what the quarters will look like.

Unknown 1
13:08 - 13:09

Okay. Thank you.

Operator
13:16 - 13:21

The next question comes from Mathias Waddesdon from SEB. Please go ahead.

Unknown 3
13:25 - 13:53

Hi. I think it was a very strong delivery in adult sales, so maybe a bit more flavor on the development there because it seems like a shift in terms of year-over-year momentum. Then perhaps also a more long-term question for you as well. I mean, do you see this part of the year growing faster maybe than the pediatric segments? Or how should we sort of view the growth trajectory for the different segments? That's the first one.

Theresa Agnew
13:55 - 15:21

Okay. Yes. Good question. So, um, as we were saying, our adult segment, uh, grew disproportionately higher, mainly due to demand from gastroenterologists and dentists. And some of the details around that, uh, Prodentis continues to grow very well in our market in Japan, as it has, uh, for a number of years. But what is new is the focus in the US on dentists. Um, so that has been a driving force for the adult sales growth. Um, they are calling on dentists together with hygienists. So doing our typical medical marketing focus, um, to build recommendations for Prodentis. So that's going very well. And now we are looking to replicate that in other markets. So in Canada we just relaunched Prodentis for dentists in Q1. So that's also contributing slightly but not to the significant level of the US. So we anticipate that Prodentis will continue to grow because of our additional effort there. And longer term, we want our adult segment to disproportionately grow. We want to continue our pediatrics growth, but because we're operating on a much smaller base with our adult business, we want to see disproportionate growth, especially with Gastrus and Prodentis.

Unknown 2
15:23 - 15:23

Come on.

Unknown 3
15:24 - 15:47

I think that's a very clear answer. Then maybe a follow up to the previous question here on costs. Do you talk about sales, sales force, marketing, investments, etc.? Um, maybe just to clarify a little bit, uh, when will we see those investments in opex for you, and how much have we seen so far? Um, maybe some clarity.

Theresa Agnew
15:50 - 16:46

Yeah. So in terms of some of those opex costs, um, we haven't seen too much of it yet. Uh, if you look at our opex increases for Q1, uh, they were primarily around clinical costs because as Alex said, you know, now we're getting back into our clinicals, recruiting a lot of patients because in Covid it was much more difficult to recruit patients. So our clinical costs, uh, increased, uh, during Q1. We anticipate, though, that the marketing and sales investments will begin to increase in the latter quarters of this year. And again, as we know, as we make those kinds of investments, it will take some time, uh, then to, uh, see the growth there. But we will be making targeted investments for sure in certain markets where we feel we have a strong opportunity to grow.

Unknown 3
16:48 - 17:24

Perfect. Sounds more like maybe the second half. Thank you at least more than the last one. Maybe to tweak a bit on the previous question as well. Uh, I appreciate you don't comment on growth going forward, but would you agree that comps are more normalized for Q2 through Q4? And then on another note, I mean, Q1 looks once again very strong. Are there some kinds of seasonality that we should continue to expect Q1 to be the strongest delivery for the company in a typical year? Or is it just, uh, sort of.

Unknown 4
17:25 - 17:27

Let's say a timing effect.

Unknown 3
17:28 - 17:32

Here in the recent two years, or how should we view that? That's my last one.

Unknown 2
17:32 - 17:32

Thank you.

Theresa Agnew
17:32 - 18:28

Yes, yes. Good question. So it is mainly a timing effect. It is orders. You know, when we had Q1 2023, it was the phasing of orders from China and the Americas, uh, that caused the big increase in Q1 of 2023. And we had some similar effects, um, in Q1 of 2024. So, so I wouldn't say there's seasonality to our business. Um, some of the things, though, that we have seen in Q1 that are very positive, such as in the US, our Amazon sales grew considerably, so 38% in our Amazon sales, so very strong in that particular channel. Uh, but again, there really isn't I would say seasonality. It's more phasing of orders because some of our distributors will place orders in certain quarters, depending on product launches and so forth.

Alexander Kotsinas
18:29 - 19:07

I can also add that, I mean, when we go more and more direct with our own subsidiaries, like we do, uh, you know, that type of spending in those, um, subsidiaries, it's more seasonal. And so that you have more campaigns in the fourth quarter, for example, compared to the first quarter. So you will have a higher activity level and higher cost level in your fourth quarter compared to the first quarter. So that is why you see, for example, now in the first quarter, part of the explanation why you have quite a strong margin now compared to the relatively weaker margin which we had in the fourth quarter. That is an effect of going direct to a larger extent.

Unknown 3
19:09 - 19:12

That's, uh, clear. Thank you very much.

Operator
19:19 - 19:25

The next question comes from Matthias Blom from Handelsbanken. Please go ahead.

Unknown 5
19:28 - 20:21

Yeah. Good morning. Thanks so much. Two questions please. Uh, firstly, coming back to the buildup of receivables in the quarter, which hampered cash flow. So. So were there large orders late in the quarter or anything you'd like to call out, or were they within the normal variation? And secondly, the Americas segment experienced a decline in sales despite Amazon platform sales being up 38%. Could you remind me what portion of USA sales is derived from the Amazon platform, just to put that 38% growth figure into perspective? Any commentary around how to think about that magnitude would be helpful. Thanks so much.

Alexander Kotsinas
20:22 - 20:52

Thank you. No, there were no large orders, uh, of any particular kind in this. So again, I think this, uh, you know, the lower, I mean, this receivable situation, it's more of a normal fluctuation, so to speak, as it happened, you know, to be like this. So it's not really any large order or anything, particularly coming in late or something like that. It's more of a, you know, it just happened to a very, to this extent, I would say.

Theresa Agnew
20:54 - 21:27

Yeah. And then on Amazon, you know we don't give the specific percentages of our channels. But I would say it's over a third of our sales for the US. Uh, Amazon is a very important channel for us in certain markets because that's where consumers shop. Because of our omnichannel approach, we need to be where the consumers are with the right message at the right time, with the right product. We focus very heavily on that channel because that's where consumers are in the US.

Unknown 5
21:29 - 22:00

Good. And just a quick follow-up question. Can you discuss the historical volatility of that growth figure for Amazon, without sharing quarter-by-quarter details? But is it typically more volatile than the rest of your sales through, you know, into the US market? Or should we consider it perhaps being superior to the rest of the group's performance in the US for the more durable? In the future.

Alexander Kotsinas
22:01 - 22:36

I can try to answer that question as well. I mean, our sales, our Amazon sales in the US are quite stable, so to speak, from quarter to quarter and are actually increasing sequentially. And essentially, we are achieving record sales nearly every quarter, so to speak. So, it's quite stable in a way. Our Amazon sales rose from one quarter to another sequentially. But then, of course, we have other businesses, other channels in the US which can be volatile, up and down to some extent, but the Amazon channel actually is quite stable, I would say, and growing.

Unknown 5
22:39 - 22:40

That's very clear.

Operator
22:46 - 22:52

The next question comes from Christopher Liljegren from Carnegie. First sentence.

Unknown 1
22:55 - 23:13

Yes. Given what you said about the legal costs in Italy continuing, although you probably won't give an exact figure here, how significant were they in the quarter? But was that the absolute majority of the one-off item cost there in Q1?

Alexander Kotsinas
23:14 - 23:22

Uh, that is correct. Yes, it was the large part. And like Theresa said, I mean, it will continue to some extent, but it will probably decline going forward. Those costs.

Unknown 2
23:22 - 23:23

Okay.

Unknown 1
23:23 - 23:49

Good. And then, coming back to the previous question here about seasonality or quarterly fluctuations, is it correct to assume that given you now have larger sales or lower direct sales than historically, that Q1 is going to be the biggest quarter and not as it was historically with Q4 being the largest quarter for BioGaia?

Unknown 2
23:53 - 23:54

Uh.

Alexander Kotsinas
23:54 - 24:26

Yes. Uh, no. So, I mean, for our direct business, it's actually I would say it's probably quarter four, which is stronger than quarter one, so to speak, because of the flu season and etc. I mean, you have a bit higher sales in the fourth quarter most probably. But still, a large part of our sales is not from direct sales. Of course, the majority is still to different distributors. And there I think it's the same as it has been previously, you know, the same quarterly variations, I would say.

Unknown 2
24:26 - 24:26

Yeah.

Theresa Agnew
24:26 - 25:25

And that part of our business, which Alex is talking about when he talks about the flu season, that's our immune health part of our business. Um, and that is highly fluctuating. So sometimes you can have an early flu season for Q4 and sometimes it's a later flu season for Q1. So that's not something we can predict. It actually happens based on flu strains and what is happening in the environment. Some of the predictors, because I've worked actually in the flu category for a long time, is you look at certain markets around the world such as Australia, and it's a prediction of what Western Europe and North America will see in terms of flu because it's going to be a similar type of flu season. So that's the only prediction we can have around flu season for Western Europe and North America.

Unknown 1
25:28 - 25:29

Okay. Thank you.

Operator
25:33 - 25:40

There are no more questions at this time, so I hand the conference back to the speakers for any closing comments.

Theresa Agnew
25:41 - 25:49

So thank you. Uh, thank you for your questions. Very good questions. Um, and we look forward to speaking with you next quarter. Thank you.

Continue to the webcast
Pierce Group, Audiocast, Q3'26
Language: English11/13/2026, 8:00 AM
Göran Dahlin Good morning, everyone, and welcome to Pierce Group's presentation of our Q3 2026 interim results. Next slide, please. I am Göran Dahlin, CEO of Pierce Group, and I am with Fredrik Kjellg…
Surgical Science Sweden, Audiocast, Q3'26
Language: English11/12/2026, 10:00 AM
Tom Englund Hi everyone, and welcome to this earnings call for Surgical Science for the third quarter of 2026. My name is Tom Englund. I am the CEO. And with me today is our CFO, Anna Ahlberg. I wil…
ExpreS2ion Biotech – Presentation of Q3 2026 Interim Report
Language: English11/12/2026, 9:00 AM
ExpreS2ion is expected to release its Q3 2026 interim report on 12 November 2026. Later the same day at 10.00, ExpreS2ion’s CEO Bent U. Frandsen and CFO Keith Alexander will present the results and answer questions in a live online event.
Meko Services AB, Q3'26
Language: English11/12/2026, 8:00 AM
Pat Thank you. Good morning, and welcome to MEKO's presentation of the third quarter of 2026. I am here with our CFO, Christy Johansson, and I will begin with an overview of the quarter and some of th…
WeSports Group, Audiocast, Q3'26
Language: English11/12/2026, 8:00 AM
Unknown 1 It. Ted Sporre Welcome to our Q3 release presentation. As you know, we have already shared preliminary figures for sales and EBITDA for this quarter, but today we complete the picture. We wi…
Nordrest Holding, Audiocast, Q3'26
Language: Swedish11/12/2026, 8:00 AM
Thomas Dahlstedt Hej och välkomna! Vi ska idag presentera Nordrests senaste kvartal och tillika resultatet för perioden. Jag som pratar nu heter Thomas Dahlstedt och är grundare och tillika VD för bol…
Karnov Group, Audiocast, Q3'26
Language: English11/12/2026, 8:00 AM
Pontus Bodelsson Welcome, everyone, to Karnov Group's earnings conference, where we will present the outcome of the third quarter of 2026. Please go to slide two. I am Pontus Bodelsson, President and…
Fasadgruppen Group, Audiocast, Q3'26
Language: English11/12/2026, 7:15 AM
Magnus Blomberg Perfect. Good morning and welcome to the Fasadgruppen presentation of our results for the third quarter 2026. My name is Magnus Blomberg. You have met me before. I am the CFO of Fasadg…
Munters AB, CMD
Language: English11/11/2026, 1:00 PM
Lena Dauvergne Good. Good afternoon everyone, and a warm welcome to Stockholm, to ESSEX and to Montage Capital Markets Day 2026. Montage Capital Markets Day 2026. It is really good to see so many of y…
Cinclus Pharma, Audiocast, Q3'26
Language: English11/11/2026, 1:00 PM
Christer Ahlberg Thank you. Hello and welcome to the Cinclus Pharma third quarter 2026 earnings call. I am Christer Ahlberg, CEO of Cinclus Pharma, and with me today is our CFO, Magnus Christensen. We…
Proact IT, CMD
Language: English11/11/2026, 12:30 PM
Unknown 1 The world of data is constantly changing. Breaches are rising, and attacks are getting more advanced. Regulation drives the need for data sovereignty. Data has to be available. Critical busi…
Ferronordic AB, Audiocast, Q3'26
Language: English11/11/2026, 9:00 AM
Henrik Good morning, everyone, and welcome to our presentation of the third quarter of 2026. During the quarter, we saw higher earnings, and growing aftermarket revenue was up 15% to 1.2 billion Swedi…
BICO, Audiocast, Q3'26
Language: English11/11/2026, 9:00 AM
Anders Fogelberg Good morning, everyone, and welcome to BICO's earnings call for the third quarter of 2026. I am Anders Fogelberg, President and CEO of BICO. And joining me today is our Group CFO, Ewa…
Catena Media, Audiocast, Q3'26
Language: English11/10/2026, 5:00 PM
Manuel Stan Good afternoon. Good evening, everyone. Welcome to the Catena Media Q3 Interim Report. I am Manuel Stan and today I'm joined by our Chief Financial Officer, Michael Gerrow. Today we will b…
Ellos Group, Q3'26
Language: English11/10/2026, 8:00 AM
Hans Ohlsson Live. Good morning, everyone, and welcome to the second presentation for Ellos Group as a listed company. We have 45 minutes today for the presentation. And there is a hard stop. After th…
Scandic Hotels Group, Audiocast, Q3'26
Language: English11/10/2026, 8:00 AM
Jens Mathisen Thank you so much, and good morning, everyone, and thank you for joining us for the Q3 presentation. I am Jens Mathisen, CEO of Scandic. And joining me is our CFO, Pierre Carstensen. We…
Svevik Industri, Q3'26
Language: Swedish11/6/2026, 9:00 AM
Johan Hårdén Tack så mycket! Hello and welcome to this hearing regarding the Q3 2026 interim report. We have an agenda where we intend to introduce ourselves to all the new shareholders as well. Kort…
Attendo, Audiocast, Q3'26
Language: English11/6/2026, 9:00 AM
Martin Tivéus Good morning, everyone, and thank you for joining us. Today, we will present our results for the third quarter of 2026. I am pleased to announce that this is the strongest quarter for At…
Cavotec, Audiocast, Q3'26
Language: English11/6/2026, 9:00 AM
David Pagels Good morning and welcome to Cavotec's Q3 2026 presentation. I am David Pagels, the CEO of Cavotec. And together with me today, I have our new CFO, Christoffer Robertsson. I would like to…
Fractal Gaming Group, Audiocast, Q3'26
Language: English11/6/2026, 9:00 AM
Jonas Good morning, everyone, and welcome to Fractal's Q3 2026 presentation. Today, we'll take you through our results, the progress that we've made, and our priorities ahead after a difficult first h…